Literature DB >> 2886491

Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases.

H H Harsch.   

Abstract

A series of nine cases of neuroleptic malignant syndrome (NMS) are presented with peak measures of autonomic dysfunction and laboratory findings. Urine abnormalities, consisting of proteinuria, casts, or cells, were an associated finding in these cases. Severe hypophosphatemia was present in two patients. Relative dehydration before the onset of the syndrome in eight of the nine patients supports the suggestion that it is a risk factor for the development of NMS. The withdrawal of dopamine agonists was also seen as a trigger for NMS. Autonomic instability and muscular rigidity occurred separately in some cases. Creatine phosphokinase elevation and fever did not necessarily parallel the duration or the degree of muscular rigidity, and this finding supports the idea of a central cause for the symptoms. A systematic approach is presented for the evaluation and treatment of NMS. Observations implicate central dopaminergic mechanisms in the regulation of autonomic functioning and the maintenance of peripheral muscle membrane stability.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886491

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  Risk factors in neuroleptic malignant syndrome.

Authors:  Vinay Gupta; Rakesh Magon; B P Mishra; G B S Sidhu; Ranjiv Mahajan
Journal:  Indian J Psychiatry       Date:  2003-01       Impact factor: 1.759

2.  Neuroleptic malignant syndrome: another medical cause of acute abdomen.

Authors:  T C Lo; M R Unwin; I W Dymock
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

3.  Case reports of neuroleptic malignant syndrome in context of quetiapine use.

Authors:  Mark B Detweiler; Kelly Sullivan; Taral R Sharma; Kye Y Kim; Jonna G Detweiler
Journal:  Psychiatr Q       Date:  2013-12

4.  Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.

Authors:  E M Jones; A Dawson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-08       Impact factor: 10.154

5.  Elevated creatine kinase does not necessarily correspond temporally with onset of muscle rigidity in neuroleptic malignant syndrome: a report of two cases.

Authors:  Koichi Nisijima
Journal:  Neuropsychiatr Dis Treat       Date:  2012-12-13       Impact factor: 2.570

Review 6.  Managing an effective treatment for neuroleptic malignant syndrome.

Authors:  Udo Reulbach; Carmen Dütsch; Teresa Biermann; Wolfgang Sperling; Norbert Thuerauf; Johannes Kornhuber; Stefan Bleich
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

7.  Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients.

Authors:  Pradyot Sarkar; Chandrashekhar Natarajan; Neeta Gode
Journal:  Indian J Psychiatry       Date:  2009 Jul-Sep       Impact factor: 1.759

8.  Neuroleptic malignant syndrome: A diagnostic challenge.

Authors:  Reshma P Ambulkar; Vijaya P Patil; Aliasgar V Moiyadi
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-10

9.  Temporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome.

Authors:  Koichi Nisijima; Katutoshi Shioda
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-18       Impact factor: 2.570

10.  Fever as a cause of hypophosphatemia in patients with malaria.

Authors:  Warren Browner; Richard Haber
Journal:  PLoS One       Date:  2007-12-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.